Introducing
ENTYCE® (capromorelin oral solution)

Finally, appetite stimulation is in your control.

Until now, there have been limited therapeutic options to restore appetite. That’s why Aratana Therapeutics created ENTYCE (capromorelin oral solution), the only FDA-approved therapeutic designed to safely and effectively stimulate appetite in dogs. ENTYCE works by mimicking ghrelin (the “hunger hormone”). Administered orally once a day, ENTYCE is appropriate to treat inappetence caused by chronic and acute conditions.

Why ENTYCE?

ENTYCE is the ONLY FDA-approved veterinary therapeutic labeled for stimulation of appetite in dogs and is an important tool in the medical management of conditions where appetite is reduced.

Inappetence Overview

More than 10 million dogs in the United States present annually to their veterinarian with the symptom of inappetence.1

Almost any disease can manifest or develop decreased appetite (hyporexia), complete lack of appetite (anorexia) or changes in appetite (dysrexia). Inappetence can be the first sign, and may be the only sign, that a dog is sick or has an underlying health condition. Prolonged inappetence, if left untreated, can become even more detrimental to the patient than the underlying primary disease.

In addition, inappetence can represent a negative perception of the quality of life to the caregiver, which may be especially distressful and is often perceived as evidence of suffering.

Learn more about inappetence >

1. Aratana data on file

Mechanism of Action

ENTYCE, a ghrelin receptor agonist, is the ONLY FDA-approved veterinary therapeutic labeled for stimulation of appetite in dogs.

Learn more >

Efficacy

The Clinical Field Study demonstrated a significantly higher proportion of inappetent dogs that received ENTYCE had increased appetite over placebo.

Learn more >

Dosing and Administration

ENTYCE provides a convenient, once-daily oral solution for treating inappetence.

Learn more >

Safety

Results of the 12-Month Laboratory Safety Study showed ENTYCE to be well tolerated in dogs.

Learn more >

Clinical References

Your convenient one-stop source for viewing and downloading important information.

Learn more >

In-Clinic Tools

Introducing ENTYCE to your clinic as a therapeutic solution specifically designed to stimulate appetite in dogs.

Learn more >

News

Keep current on all the latest Aratana news, upcoming conferences and other timely information.

Learn more >

IMPORTANT SAFETY INFORMATION: ENTYCE® (capromorelin oral solution) is for use in dogs only. Do not use in breeding, pregnant or lactating dogs. Use with caution in dogs with hepatic dysfunction or renal insufficiency. Adverse reactions in dogs may include diarrhea, vomiting, polydipsia, and hypersalivation. Should not be used in dogs that have a hypersensitivity to capromorelin. Please see the full Prescribing Information for more detail.

ENTYCE is Now Available

Other therapeutics from Aratana

Nocita Logo

NOCITA® (bupivacaine liposome injectable suspension)

provides post-operative pain relief for cranial cruciate ligament surgery for up to 72 hours.

Now you can be sure dogs are getting the post-surgical pain relief they need even after they leave your clinic.

IMPORTANT SAFETY INFORMATION: NOCITA® (bupivacaine liposome injectable suspension) is for use in dogs only. Do not use in dogs younger than 5 months of age, dogs used for breeding, or in pregnant or lactating dogs. Do not administer by intravenous or intra-arterial injection. Adverse reactions in dogs may include discharge from incision, incisional inflammation and vomiting. Avoid concurrent use with bupivacaine HCl, lidocaine or other amide local anesthetics. Please see the full Prescribing Information for more detail.